|
[资源]
EBR - April 2019
The European Biopharmaceutical Review (EBR), is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the pan European biopharmaceutical market across Europe, North America & the rest of the developed world. The editorial covers in-depth articles, case studies, meeting and report reviews written by specialists with "hands-on" experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with 'regular feature sections on: Biobusiness, Science and Innovation, Biodiscovery, Biodevelopment, Biomanufacturing plus special focuses on geographic or therapeutic territories. Established in 1997, EBR is now well-recognised for providing beneficial information to players in the bio-industry including entrepreneurial biopharmaceutical and more general life science companies, large pharma companies, supplier groups, regulators, investors, analysts and consultants, thus providing a unique forum for general review of the European life science sector on a regular basis
0308635056.png |
» 本帖附件资源列表
-
欢迎监督和反馈:小木虫仅提供交流平台,不对该内容负责。
本内容由用户自主发布,如果其内容涉及到知识产权问题,其责任在于用户本人,如对版权有异议,请联系邮箱:libolin3@tal.com
- 附件 1 : EBR_-_April_2019.pdf
2019-03-21 15:53:31, 6.19 M
» 猜你喜欢
|